Mevalonate pathway contributed to simvastatin induced apoptosis, proliferation inhibition and deactivation of PI3K/Akt and MAPK/ERK pathways in breast cancer cells (Figure 4). This evidence concerns the gene AKT1 and breast carcinoma.